Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities
Authors:
- Chiara LazzariCLChiara Lazzari
- Alessandra BulottaABAlessandra Bulotta
- Maria Giulia CangiMCMaria Giulia Cangi
- Gabriele BucciGabriele Bucci
- Lorenza PecciariniLPLorenza Pecciarini
- Silvia BonfiglioSBSilvia Bonfiglio
- Vincenza LorussoVLVincenza Lorusso
- Stefania IppatiSIStefania Ippati
- Gianluigi ArrigoniGAGianluigi Arrigoni
- Greta GrassiniGGGreta Grassini
- Claudio DoglioniCDClaudio Doglioni
- Vanesa GregorcVGVanesa Gregorc
Open Access
- 15 December 2020
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 10 (12) , 1092
Abstract
Lung cancer remains the first cause of cancer-related deaths worldwide. Thanks to the improvement in the knowledge of the biology of non-small cell lung cancer (NSCLC), patients’ survival has significantly improved. A growing number of targetable molecular alterations have been identified. Next-generation sequencing (NGS) has become one of the methodologies entered in clinical practice and was recently recommended by the European society for medical oncology (ESMO) to perform a comprehensive molecular characterization in patients with cancer. The current review provides an overview of the clinical trials that have explored the impact of NGS in patients with cancer, its limits, and advantages.Keywords
This publication has 33 references indexed in Scilit:
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCancer Discovery, 2015
- Next-generation sequencing to guide cancer therapyGenome Medicine, 2015
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Clinical Cancer Research, 2015
- In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting OpportunitiesCancer Cell, 2015
- Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid TumorsCancer Discovery, 2015
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicineNature Medicine, 2014
- Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer GenomeCell, 2013
- Functional impact bias reveals cancer driversNucleic Acids Research, 2012
- MuSiC: Identifying mutational significance in cancer genomesGenome Research, 2012